Lobaplatin vs Carboplatin before surgery for HER2+ breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests two different chemotherapy drugs, lobaplatin or carboplatin, given before surgery to shrink HER2-positive breast tumors. It aims to see which drug works better and is safer for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been newly diagnosed with breast cancer.
- You are a woman between 18 and 70 years old.
- Your cancer is HER2-positive (a specific protein marker).
- Your tumor is at least 2 cm or has spread to nearby lymph nodes (stage T1c N1-2 or T2-4 N0-2).
- You have not had chemotherapy, hormone therapy, or immunotherapy for breast cancer in the last 4 weeks.
- You have not had cancer treatment with certain immunotherapy drugs (like anti-PD-1 or anti-CTLA-4) before.
- Your heart, liver, kidney, and blood cell counts are within normal limits (you'll have tests to check).
- You are not pregnant, breastfeeding, or planning to become pregnant, and agree to use birth control if needed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two different combinations of chemotherapy and targeted therapy given before surgery for HER2-positive breast cancer. The goal is to see which combination works better at shrinking the tumor.
This Phase 2 trial compares nab-PH plus pyrrolitinib versus TCbHP as treatment given before breast surgery. It aims to see which option works better and is safe for people with HER2-positive invasive breast cancer.
This trial compares two different drug combinations given before surgery to shrink HER2-positive breast cancer tumors. The goal is to see which combination works better and has fewer side effects.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
This phase 3 trial compares two pre-surgery treatment plans for people with HER2-positive invasive breast cancer that has spread to nearby lymph nodes. It aims to see which plan works better to shrink the tumor before surgery and improve outcomes.
This trial tests a combination of two targeted drugs (pyrotinib and trastuzumab) plus chemotherapy (capecitabine) given before surgery to shrink HER2-positive breast cancer. The goal is to see if this treatment can make the cancer disappear before surgery.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.